A Phase 3 interventional study of cetuximab + cisplatin + vinorelbine and cisplatin + vinorelbine in Non Small Cell Lung Cancer (NSCLC), sponsored by Merck KGaA, Darmstadt, Germany. Completed at 118 sites in 28 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-06-25.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 52 studies testing cetuximab in Carcinoma, Non-Small-Cell Lung — 2 open to participants now, 2 under way, none of them phase 3. Cetuximab · Carcinoma, Non-Small-Cell Lung.
Among the 52 studies testing cetuximab in Carcinoma, Non-Small-Cell Lung, this one has the largest enrollment of the 51 interventional ones that give a count, is one of 8 that started in 2004, is one of 5 in phase 3, and was the 15th registered.
7,638 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →2 of the 52 studies testing cetuximab in Carcinoma, Non-Small-Cell Lung are open now, in 2 countries. Recruiting first, the newest first:
Sun Yat-sen University · Sites in China
Ages 18+
Jonathan Riess · Sites in United States
Ages 18+
By country, each count listing its studies:
Cetuximab: first FDA approval 2004 (ERBITUX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
52 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 38 · Phase 3 6
First in 2000; this study’s year is marked. 8 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,861 is above the median of 62 across 6,031 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 63 across the 51 interventional studies. Of the 47 that completed or were terminated, 22 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 52 have an industry lead sponsor. The 10 most frequent:
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
35 studies in Carcinoma, Non-Small-Cell Lung by Merck KGaA, Darmstadt, Germany: 1 open now, 4 under way, 1 of them phase 3. Of 30 finished, 24 (80%) have results posted.
Among the 35 studies in Carcinoma, Non-Small-Cell Lung by Merck KGaA, Darmstadt, Germany, this one has the largest enrollment of the 34 interventional ones that give a count, is the only one that started in 2004, is one of 9 in phase 3, and was the 4th registered.
Merck KGaA, Darmstadt, Germany’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 52 studies testing cetuximab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck KGaA, Darmstadt, Germany’s 35 in Carcinoma, Non-Small-Cell Lung:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to investigate the efficacy of cetuximab in combination with chemotherapy in comparison to chemotherapy alone in patients with advanced non small cell lung cancer who did not received prior chemotherapy. Overall survival will be taken as primary measure of efficacy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
cetuximab + cisplatin + vinorelbine
Drug: cetuximab + cisplatin + vinorelbine
cisplatin + vinorelbine alone
Drug: cisplatin + vinorelbine
Drug pages: CetuximabStudies of CetuximabCetuximab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · CisplatinStudies of CisplatinCisplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · VinorelbineStudies of VinorelbineVinorelbine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
cetuximab given as an intravenous (i.v.) infusion every week (400mg/m\^2 initial dose and 250mg/m\^2 subsequent doses) until progressive disease (PD) + cisplatin 80mg/m\^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m\^2 i.v. infusion on days 1 and 8 of each 3-week cycle.
Drug pages: CisplatinStudies of CisplatinCisplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · VinorelbineStudies of VinorelbineVinorelbine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
cisplatin 80mg/m\^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m\^2 i.v. infusion on days 1 and 8 of each 3-week cycle.
Overall Survival Time (OS)
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier.
Time frame: Time from randomisation to death or last day known to be alive, reported between day of first patient randomised, Oct 2004, until cut-off date 18 Jul 2007
Progression-free Survival Time
Duration from randomization until radiological progression (based on modified World Health Organisation (WHO) criteria) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment.
Time frame: Time from randomization to disease progression, death or last tumor assessment, reported between day of first patient randomised, Oct 2004, until cut-off date 18 Jul 2007
Best Overall Response Rate
The best overall response rate is defined as the proportion of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria).
Time frame: Evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, Oct 2004, until cut-off date 18 Jul 2007
Disease Control Rate
The disease control rate is defined as the proportion of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease as best overall response according to radiological assessments (based on modified WHO criteria).
Time frame: Evaluations were performed every 6 weeks until progression, reported between day of first patient randomised, Oct 2004, until cut-off date 18 Jul 2007
Quality of Life (QOL) Assessment European Organisation for the Research and Treatment of Cancer (EORTC) QLQ-C30 Global Health Status
Mean global health status scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a better QoL.
Time frame: at baseline, at cycle 3, at month 6, reported between day of first patient randomised, Oct 2004, until cut-off date 18 Jul 2007
Quality of Life Assessment (EORTC QLQ-C30) Social Functioning
Mean social functioning scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a higher level of functioning.
Time frame: at baseline, at cycle 3, at month 6, reported between day of first patient randomised, Oct 2004, until cut-off date 18 Jul 2007
A Population Pharmacokinetic (PK) Analysis for Cetuximab in Non-Small Cell Lung Cancer (NSCLC) - Serum Cetuximab Concentrations
Population PK analysis was conducted using non-linear mixed effects modeling (NONMEM) software, integrating the PK data from this study and the Phase II study EMR 62 202-011.
Time frame: Week 1, Day 1: baseline and end of infusion; Week 7, Day 43: within 12 h after cetuximab administration.
Safety - Number of Patients Experiencing Any Adverse Event
Please refer to Adverse Events section for further details
Time frame: time from first dose up to 30 after last dose of study treatment, reported between day of first patient randomised, Oct 2004, until cut-off date 18 Jul 2007
First/last subject (informed consent): October 2004/January 2006. Clinical data cut-off: 18 July 2007. Last subject completed 16 May 2012. Subjects randomized at 155 centers; Asia/Australia: 21; Europe: 120; South America: 14.
| Milestone | Cetuximab Plus Chemotherapy | Chemotherapy Alone |
|---|---|---|
| Started | 557 | 568 |
| Completed | 557 | 568 |
| Not completed | 0 | 0 |
Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier.
| months | Cetuximab Plus Chemotherapy | Chemotherapy Alone |
|---|---|---|
| Overall Survival Time (OS) | 11.3 (9.4 to 12.4) | 10.1 (9.1 to 10.9) |
Duration from randomization until radiological progression (based on modified World Health Organisation (WHO) criteria) or death due to any cause. Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment.
| months | Cetuximab Plus Chemotherapy | Chemotherapy Alone |
|---|---|---|
| Progression-free Survival Time | 4.8 (4.2 to 5.3) | 4.8 (4.4 to 5.4) |
The best overall response rate is defined as the proportion of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria).
| percentage of participants | Cetuximab Plus Chemotherapy | Chemotherapy Alone |
|---|---|---|
| Best Overall Response Rate | 36.4 (32.4 to 40.6) | 29.2 (25.5 to 33.2) |
The disease control rate is defined as the proportion of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease as best overall response according to radiological assessments (based on modified WHO criteria).
| percentage of participants | Cetuximab Plus Chemotherapy | Chemotherapy Alone |
|---|---|---|
| Disease Control Rate | 72.5 (68.6 to 76.2) | 71.5 (67.6 to 75.2) |
Mean global health status scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a better QoL.
| scores on a scale | Cetuximab Plus Chemotherapy | Chemotherapy Alone |
|---|---|---|
| At baseline | 45.72 ± 2.164 | 46.36 ± 2.138 |
| At cycle 3 | 48.33 ± 2.325 | 51.55 ± 2.464 |
| At month 6 | 54.71 ± 2.729 | 52.92 ± 2.787 |
Mean social functioning scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a higher level of functioning.
| scores on a scale | Cetuximab Plus Chemotherapy | Chemotherapy Alone |
|---|---|---|
| At baseline | 66.17 ± 2.836 | 64.73 ± 2.825 |
| At cycle 3 | 58.05 ± 2.995 | 67.13 ± 3.138 |
| At month 6 | 67.36 ± 3.449 | 66.47 ± 3.515 |
Population PK analysis was conducted using non-linear mixed effects modeling (NONMEM) software, integrating the PK data from this study and the Phase II study EMR 62 202-011.
| ug/mL | Cetuximab Concentration at End of Infusion Week 1 | Cetuximab Concentration Before Infusion Week 7 |
|---|---|---|
| A Population Pharmacokinetic (PK) Analysis for Cetuximab in Non-Small Cell Lung Cancer (NSCLC) - Serum Cetuximab Concentrations | 223.1 ± 64.6 | 51.5 ± 33.1 |
Please refer to Adverse Events section for further details
| participants | Cetuximab Plus Chemotherapy | Chemotherapy Alone |
|---|---|---|
| Safety - Number of Patients Experiencing Any Adverse Event | 545 | 549 |
Collected over Time from first dose up to 30 days after the last dose of study treatment.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cetuximab Plus Chemotherapy | — | 325/548 (59.3%) | 532/548 (97.1%) |
| Chemotherapy Alone | — | 244/562 (43.4%) | 537/562 (95.6%) |
| Event | Cetuximab Plus Chemotherapy | Chemotherapy Alone |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 96/548 | 67/562 |
| NeutropeniaBlood and lymphatic system disorders | 47/548 | 33/562 |
| General physical health deteriorationGeneral disorders | 22/548 | 4/562 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 20/548 | 13/562 |
| PneumoniaInfections and infestations | 19/548 | 13/562 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 18/548 | 13/562 |
| VomitingGastrointestinal disorders | 16/548 | 14/562 |
| PyrexiaGeneral disorders | 16/548 | 6/562 |
| LeukopeniaBlood and lymphatic system disorders | 15/548 | 8/562 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 14/548 | 9/562 |
| Event | Cetuximab Plus Chemotherapy | Chemotherapy Alone |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 302/548 | 324/562 |
| NauseaGastrointestinal disorders | 291/548 | 303/562 |
| AnaemiaBlood and lymphatic system disorders | 226/548 | 264/562 |
| RashSkin and subcutaneous tissue disorders | 249/548 | 17/562 |
| VomitingGastrointestinal disorders | 214/548 | 225/562 |
| AnorexiaMetabolism and nutrition disorders | 208/548 | 202/562 |
| ConstipationGastrointestinal disorders | 204/548 | 189/562 |
| FatigueGeneral disorders | 202/548 | 181/562 |
| LeukopeniaBlood and lymphatic system disorders | 176/548 | 155/562 |
| DiarrhoeaGastrointestinal disorders | 126/548 | 103/562 |
| Age, Continuous(years) | Cetuximab Plus Chemotherapy | Chemotherapy Alone | Total |
|---|---|---|---|
| Median | 59 (18 to 78) | 60 (20 to 83) | 59 (18 to 83) |
| Age, Customized(participants) | Cetuximab Plus Chemotherapy | Chemotherapy Alone | Total |
|---|---|---|---|
| <18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 385 | 389 | 774 |
| >=65 years | 172 | 179 | 351 |
| Sex: Female, Male(Participants) | Cetuximab Plus Chemotherapy | Chemotherapy Alone | Total |
|---|---|---|---|
| Female | 172 | 163 | 335 |
| Male | 385 | 405 | 790 |
| Region of Enrollment(participants) | Cetuximab Plus Chemotherapy | Chemotherapy Alone | Total |
|---|---|---|---|
| Australia | 20 | 23 | 43 |
| Hong Kong | 2 | 2 | 4 |
| Singapore | 5 | 5 | 10 |
| Korea, Republic of | 28 | 26 | 54 |
| Taiwan | 21 | 22 | 43 |
| Austria | 9 | 7 | 16 |
| Belgium | 3 | 10 | 13 |
| Bulgaria | 12 | 12 | 24 |
| Czech Republic | 12 | 17 | 29 |
| France | 25 | 25 | 50 |
| Germany | 91 | 88 | 179 |
| Hungary | 21 | 23 | 44 |
| Ireland | 3 | 4 | 7 |
| Netherlands | 10 | 10 | 20 |
| Poland | 59 | 50 | 109 |
| Portugal | 3 | 0 | 3 |
| Russian Federation | 23 | 16 | 39 |
| Slovakia | 8 | 12 | 20 |
| Spain | 16 | 13 | 29 |
| Sweden | 6 | 3 | 9 |
| Switzerland | 10 | 6 | 16 |
| Turkey | 1 | 2 | 3 |
| United Kingdom | 23 | 21 | 44 |
| Ukraine | 56 | 71 | 127 |
| Chile | 10 | 16 | 26 |
| Italy | 18 | 23 | 41 |
| Argentina | 5 | 2 | 7 |
| Mexico | 9 | 8 | 17 |
| Brazil | 48 | 51 | 99 |
Showing the first 100 of 118 sites across 28 countries. Choose a country and city above to see the rest.
The record gives a start of Oct 2004, a primary completion of Jul 2007 and a completion of May 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2011, 4 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cetuximab · Cisplatin · Vinorelbine
Carcinoma, Non-Small-Cell Lung →
Merck KGaA, Darmstadt, Germany →